vTv Therapeutics (VTVT) Announces Completion of Phase 2 LOGRA Enrollment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. BMY
8. FIX
9. TSCO
10. BE

Go back to vTv Therapeutics (VTVT) Announces Completion of Phase 2 LOGRA Enrollment

vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes

August 16, 2016 7:00 AM EDT

TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential

Company Releases Q2 Earnings Results and Details Upcoming Program Milestones

HIGH POINT, N.C.--(BUSINESS WIRE)-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimers disease and diabetes, today announced the completion of enrollment of the companys Phase 2 LOGRA (aLlosteric Oral Glp1 Receptor Agonist) study, a randomized, double-blind, placebo-controlled, parallel group trial... More